Patient Acceptance of Half-dose Vs. Half-time Molecular Breast Imaging.

Objective: A number of strategies have been implemented at our institution to allow reductions in the administered dose or imaging time for molecular breast imaging (MBI). In this work, we examine patient opinions of whether dose reduction or time reduction is preferred.

Methods: Sixty female volunteers were randomized to undergo MBI at either half-dose (150 MBq Tc-99m sestamibi; images acquired for 10 minutes per view) or half-time (300 MBq Tc-99m sestamibi; images acquired for 5 minutes per view).

Guidelines for Quality Control Testing of Molecular Breast Imaging Systems.

Molecular breast imaging (MBI) is a nuclear medicine test that uses dedicated γ-cameras designed for imaging of the breast. Despite growing adoption of MBI, there is currently a lack of guidance on appropriate quality control procedures for MBI systems. Tests designed for conventional γ-cameras either do not apply or must be modified for dedicated detectors.

Molecular Breast Imaging: Administered Activity Does Not Require Adjustment Based on Patient Size.

At our institution, molecular breast imaging (MBI) is performed with 300 MBq of Tc-sestamibi for all patients. For some nuclear medicine procedures, administered activity or imaging time is increased for patients of larger size to obtain adequate counts. Our objective was to assess whether uptake of Tc-sestamibi in the breast is influenced by patient size.